Literature DB >> 23564004

How to best measure HIV reservoirs?

Christine Rouzioux1, Douglas Richman.   

Abstract

PURPOSE OF REVIEW: The persistence of HIV within infected CD4 T cells is a major obstacle to eradication, and assessment of the strategies to reduce HIV reservoirs is one of the major challenges. Measuring HIV reservoirs accurately will be necessary to assess those strategies. The objective of this review is to present the most recent studies that may help to define the best markers to measure HIV reservoirs. RECENT
FINDINGS: Recent findings have shown that multiple assays can be used to quantify the different analytes that reflect the HIV reservoirs. They have provided new insights, but lack of standardization has made cross-comparisons of data difficult. No single best assay for measuring HIV reservoirs has been identified and these assays often address different questions, such as the size of the reservoirs, the composition of the reservoirs, or the capacity of latent reservoirs to produce virus. A consensus on what values reflect robust conclusions will have to wait for the generation of additional results.
SUMMARY: In conclusion, there is a compelling need for investigators to optimize assays and share protocol reagents and specimens to permit the validation, comparison, and standardization of techniques. There is an important need for validated, high-throughput, sensitive, and accurate assays that can detect changes in HIV reservoir size in order to assess the impact of candidate therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23564004      PMCID: PMC3763804          DOI: 10.1097/COH.0b013e32835fc619

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  56 in total

Review 1.  The role of HIV-DNA testing in clinical practice.

Authors:  Gabriella d'Ettorre; Lorenzo Zaffiri; Giancarlo Ceccarelli; Claudio M Mastroianni; Vincenzo Vullo
Journal:  New Microbiol       Date:  2010-01       Impact factor: 2.479

2.  Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection.

Authors:  Laurent Hocqueloux; Thierry Prazuck; Véronique Avettand-Fenoel; Alain Lafeuillade; Bernard Cardon; Jean-Paul Viard; Christine Rouzioux
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

3.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

4.  Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort.

Authors:  Jade Ghosn; Christiane Deveau; Marie-Laure Chaix; Cécile Goujard; Julie Galimand; Yasmine Zitoun; Thierry Allègre; Jean-François Delfraissy; Laurence Meyer; Christine Rouzioux
Journal:  J Antimicrob Chemother       Date:  2010-02-18       Impact factor: 5.790

Review 5.  Introduction: challenges to finding a cure for HIV infection.

Authors:  Douglas D Richman
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

6.  Immunologic and virologic events in early HIV infection predict subsequent rate of progression.

Authors:  Anuradha Ganesan; Pratip K Chattopadhyay; Tess M Brodie; Jing Qin; Wenjuan Gu; John R Mascola; Nelson L Michael; Dean A Follmann; Mario Roederer
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

7.  Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection.

Authors:  Adrian Schmid; Sara Gianella; Viktor von Wyl; Karin J Metzner; Alexandra U Scherrer; Barbara Niederöst; Claudia F Althaus; Philip Rieder; Christina Grube; Beda Joos; Rainer Weber; Marek Fischer; Huldrych F Günthard
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

8.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

9.  Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS.

Authors:  Thomas W North; Joanne Higgins; Jesse D Deere; Timothy L Hayes; Andradi Villalobos; Lourdes Adamson; Barbara L Shacklett; Raymond F Schinazi; Paul A Luciw
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

10.  Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.

Authors:  Erin H Graf; Angela M Mexas; Jianqing J Yu; Farida Shaheen; Megan K Liszewski; Michele Di Mascio; Stephen A Migueles; Mark Connors; Una O'Doherty
Journal:  PLoS Pathog       Date:  2011-02-24       Impact factor: 6.823

View more
  25 in total

1.  Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size.

Authors:  Marilia Rita Pinzone; Erin Graf; Lindsay Lynch; Brigit McLaughlin; Frederick M Hecht; Mark Connors; Stephen A Migueles; Wei-Ting Hwang; Giuseppe Nunnari; Una O'Doherty
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

2.  Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.

Authors:  Caroline Pereira Bittencourt Passaes; Timothée Bruel; Jérémie Decalf; Annie David; Mathieu Angin; Valerie Monceaux; Michaela Muller-Trutwin; Nicolas Noel; Katia Bourdic; Olivier Lambotte; Matthew L Albert; Darragh Duffy; Olivier Schwartz; Asier Sáez-Cirión
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

3.  Identification, Localization, and Quantification of HIV Reservoirs Using Microscopy.

Authors:  Lisa Prevedel; Nancy Ruel; Paul Castellano; Carla Smith; Shaily Malik; Courtney Villeux; Morgane Bomsel; Susan Morgello; Eliseo A Eugenin
Journal:  Curr Protoc Cell Biol       Date:  2018-09-28

Review 4.  Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Authors:  Nancie M Archin; Julia Marsh Sung; Carolina Garrido; Natalia Soriano-Sarabia; David M Margolis
Journal:  Nat Rev Microbiol       Date:  2014-11       Impact factor: 60.633

Review 5.  Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.

Authors:  David M Margolis; Nancie M Archin
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

6.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

7.  Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control.

Authors:  Christopher W Pohlmeyer; Veronica D Gonzalez; Alivelu Irrinki; Ricardo N Ramirez; Li Li; Andrew Mulato; Jeffrey P Murry; Aaron Arvey; Rebecca Hoh; Steven G Deeks; George Kukolj; Tomas Cihlar; Stefan Pflanz; Garry P Nolan; Gundula Min-Oo
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

8.  Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.

Authors:  Aya Ishizaka; Hidenori Sato; Hitomi Nakamura; Michiko Koga; Tadashi Kikuchi; Noriaki Hosoya; Tomohiko Koibuchi; Akio Nomoto; Ai Kawana-Tachikawa; Taketoshi Mizutani
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

9.  Ultrasensitive Immunoassay for Simian Immunodeficiency Virus p27CA.

Authors:  Adrienne E Swanstrom; Robert J Gorelick; Guoxin Wu; Bonnie Howell; Anitha Vijayagopalan; Rebecca Shoemaker; Kelli Oswald; Siddhartha A Datta; Brandon F Keele; Gregory Q Del Prete; Elena Chertova; Julian W Bess; Jeffrey D Lifson
Journal:  AIDS Res Hum Retroviruses       Date:  2018-07-10       Impact factor: 2.205

Review 10.  Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era.

Authors:  Valeria Cento; Carlo Federico Perno
Journal:  Diagnostics (Basel)       Date:  2021-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.